Basilea to regain full global rights to ceftobiprole
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG / Basilea to regain full global rights to ceftobiprole processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, February 19, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN)
announces that after the negative decision by the CHMP today, Cilag GmbH
International, a Johnson & Johnson company, has given notice that it will return
global rights of ceftobiprole to Basilea.
The European Committee for Medicinal Products for Human Use (CHMP) indicated
today that the study results of the clinical phase III program of ceftobiprole
for the treatment of complicated skin and soft tissue infections (cSSTI)
suggested that the drug was beneficial to patients. The Committee, however,
adopted a negative opinion on the Market Authorization Application (MAA) due to
concerns about the reliability of the results of the phase III studies
supporting the MAA, stating that the studies had not been conducted in
compliance with "good clinical practice" (GCP) in some sites.
Cilag GmbH International informed Basilea today of its notice of termination of
the License Agreement for ceftobiprole after the CHMP's negative decision.
"The CHMP indicated today that study results suggested that ceftobiprole was
beneficial to patients. The rejection of the New Drug Application (NDA) and MAA
by health authorities in the U.S. and EU, respectively, because of data
integrity issues have led to significant delays in ceftobiprole being available
to patients with potentially life-threatening resistant bacterial infections,"
commented Dr. Anthony Man, Chief Executive Officer of Basilea. "We are pleased
to gain full control of the development and commercialization of ceftobiprole.
Basilea is committed to take those steps necessary to allow ceftobiprole to be
more widely available to patients. We are reviewing all strategic options to
protect the interests of Basilea and its shareholders."
Due to the deficiencies identified by the U.S. Food and Drug Administration
(FDA) in Johnson & Johnson PRD's conduct of the clinical investigations and
Basilea's claim that Johnson & Johnson PRD breached the License Agreement,
Basilea submitted a Request for Arbitration under the License Agreement for
ceftobiprole in February 2009. Basilea's claims under arbitration include that
Johnson & Johnson PRD breached the License Agreement by, among other things,
causing the delay in the approval of ceftobiprole in the U.S. and the EU.
Basilea will now focus on its damage claims under arbitration and anticipates an
arbitration decision prior to the end of 2010.
Under the terms of the License Agreement, there will be a one-year transition
period during which Cilag is required to fulfill all its obligations under the
Agreement, including but not limited to development, manufacturing and
commercialization. In a next step both parties need to agree on a transition
plan that ensures proper management of ongoing clinical and regulatory
activities, commercialization and manufacturing and allows for an efficient
handover at no cost to Basilea.
Regulatory key events
In February 2010, the CHMP adopted a negative opinion on the MAA for
ceftobiprole for the treatment of cSSTI. The MAA for ceftobiprole for the
treatment of cSSTI had been filed by Janssen-Cilag in June 2007. After a
positive opinion from the CHMP in November 2008, the European Medicines Agency
took the unusual step of halting the European Commission authorization process
on ceftobiprole pending completion and assessment of Good Clinical Practice
(GCP) inspections.
The CHMP stated that inspections showed that the phase III studies supporting
the MAA had not been conducted in compliance with GCP in some sites. Although
the study results suggested that the medicine was beneficial to patients, the
CHMP was concerned about how reliable the results were. The Committee therefore
recommended that, in light of the uncertainty surrounding the results,
ceftobiprole should not be granted marketing authorization.
In December 2009, the FDA issued to the sponsor, Johnson & Johnson PRD, a
Complete Response Letter on ceftobiprole for the treatment of complicated skin
and skin structure infections (cSSSI), indicating that the Agency cannot approve
the NDA in its present form. In order to address the deficiencies, the FDA
recommended that two new, adequate, and well-controlled studies to evaluate the
safety and efficacy ofceftobiprole for the treatment of cSSSI should be
conducted. Johnson & Johnson PRD communicated at that time that it intended to
discuss the best path forward with the FDA as soon as possible.
In August 2009, the FDA issued to Johnson & Johnson PRD a Warning Letter on its
role as a sponsor of clinical trials. The Agency noted that under the terms of
the agreement between Basilea and Cilag GmbH International, a Johnson & Johnson
company, all rights and responsibilities for ceftobiprole clinical trials were
transferred to Johnson & Johnson PRD and the FDA concluded that Johnson &
Johnson PRD did not adhere to the applicable statutory requirements or FDA
regulations governing the conduct of clinical investigations. The FDA found
numerous objectionable conditions during its investigation into Johnson &
Johnson PRD's role as a sponsor of the two phase III trials of ceftobiprole for
the treatment of cSSSI.
Basilea granted Cilag GmbH International an exclusive worldwide license to
develop, manufacture and commercialize ceftobiprole in February 2005.
About ceftobiprole
Ceftobiprole is an anti-MRSA broad-spectrum cephalosporin antibiotic exhibiting
activity against a wide spectrum of Gram-positive bacteria, including the
'superbug' methicillin-resistant Staphylococcus aureus (MRSA) and
penicillin-resistant Streptococcus pneumonia as well as many clinically
important Gram-negative bacteria, including Pseudomonas. Ceftobiprole is
marketed in Canada (ZEFTERA(TM)) for the treatment of cSSSI, including non-limb
threatening diabetic foot infections without concomitant osteomyelitis and in
Switzerland (Zevtera(TM)) for the treatment of cSSTI including diabetic foot
infections without concomitant osteomyelitis.
Conference call
Basilea Pharmaceutica Ltd. invites you to participate in a conference call on
Friday, February 19, 2010, 3:00 p.m (CET), during which the company will discuss
today's press release.
Dial-in numbers are:
+41 (0) 91 610 56 00(Europe and ROW)
+1 (1) 866 291 4166 (USA)
+44 (0) 207 107 0611 (UK)
A playback will be available 1 hour after the conference call until Tuesday,
February 23, 2010, 6 p.m. (CET). Participants requesting a digital playback may
dial:
+41 (0) 91 612 4330 (Europe)
+1 (1) 866 416 2558 (USA)
+44 (0) 207 108 6233 (UK)
and will be asked to enter the ID 14060 followed by the # sign.
About Basilea
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on
the SIX Swiss Exchange (SIX:BSLN). Basilea's integrated research and development
operations are currently focused on new antibacterial, antifungal and oncology
agents to fight drug resistance and on the development of dermatology drugs.
Basilea's products are targeted to satisfy high medical and patient needs in the
hospital and specialty care setting.
The company owns a diversified portfolio including two commercialized drugs
(Toctino®, ZEFTERA(TM)/ Zevtera(TM)) and one investigational drug
(isavuconazole) in phase III clinical development. Toctino® (alitretinoin) is
marketed in Denmark, France, Germany, Switzerland and the United Kingdom and is
approved in Austria, Belgium, Canada, Finland, Luxemburg, the Netherlands and
Spain. Toctino® has been recommended for approval in 16 additional European
countries. Furthermore, a phase III clinical program on alitretinoin for the
treatment of severe chronic hand eczema is ongoing in the U.S.
Ceftobiprole is marketed in Canada under the brand name ZEFTERA(TM) and in
Switzerland under Zevtera(TM). Basilea has set up commercial organizations in
Canada, France, Germany, the Nordics, Switzerland and the United Kingdom, while
it is building sales and marketing organizations in other countries to
commercialize alitretinoin.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new information,
future events or otherwise.
For further information, please contact:
+----------------------------------------+-------------------------------------+
|Media Relations |Investor Relations |
+----------------------------------------+-------------------------------------+
|Adesh Kaul |Barbara Zink, Ph.D., MBA |
|Head Public Relations & |Head Corporate Development |
|Corporate Communications |+41 61 606 1233 |
|+41 61 606 1460 | |
|media_relations(at)basilea.com |investor_relations(at)basilea.com |
|
+----------------------------------------+-------------------------------------+
This press release can be downloaded fromwww.basilea.com
The press release can also be downloaded from the following link:
[HUG#1386625]
--- End of Message ---
Basilea Pharmaceutica AG
Grenzacherstrasse 487
P.O Box Basel Switzerland
WKN: A0B9GA;ISIN: CH0011432447;
Press release (PDF): http://hugin.info/134390/R/1386625/345229.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.02.2010 - 08:49 Uhr
Sprache: Deutsch
News-ID 1010648
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Basel
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 194 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Basilea to regain full global rights to ceftobiprole
"
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
